Product Centre

Our pipeline of drug candidates currently consists of nine monoclonal antibody drugs, three of which are our Core Products under phase III clinical trials.

  • CMAB007 (omalizumab)

    • A recombinant humanized anti-IgE monoclonal antibody
    • Our new drug candidate for treatment of asthma patients who remain inadequately controlled despite med/high dose of ICS plus LABA
    • The only mAb asthma therapy developed in China by a local Chinese company that had reached phase III clinical trial according to Frost & Sullivan, once approved by the NMPA, it will be the first mAb asthma therapy developed by a local Chinese company marketed in China
    • CMAB007 combines with free IgE to form an anti-IgE complex that inhibits the high affinity IgE receptor and thereby prevents the allergic response
  • The mechanism of action of CMAB007

  • CMAB009 (cetuximab)

    • A recombinant anti-EGFR chimeric monoclonal antibody
    • Our new drug candidate based on cetuximab for first-line treatment of metastatic colorectal cancer (“mCRC”) in combination with FOLFIRI
    • Uses CHO expression system, which is different from the mouse myeloma cell SP2/0 expression system used in the currently marketed cetuximab product
    • The first NMPA approved chimeric anti-EGFR antibody for clinical trial developed in China by a local Chinese company
    • Significantly reduces immunogenicity and decreases the incidence of adverse reactions, such as severe hypersensitivity based on our clinical results compared to published clinical results for marketed cetuximab product
  • The mechanism of action of CMAB009

  • CMAB008 (infliximab)

    • A recombinant anti-TNF-alpha chimeric monoclonal antibody
    • Our new drug candidate based on infliximab for moderate to severe active rheumatoid arthritis
    • Potentially one of the best in class of chimeric anti-TNF-alpha antibody in China
    • The first NMPA approved chimeric anti-TNF-alpha antibody for clinical trial developed in China by a local Chinese company
  • The mechanism of action of CMAB008

We also have a pipeline of six other drug candidates that includes our versions of trastuzumab, nivolumab and adalimumab, all of which have the potential to become key products for the treatment of cancers or autoimmune diseases in the future.

CMAB819 (nivolumab)

CMAB819 (nivolumab) is our phase I clinical trial new drug candidate. CMAB819 was approved by NMPA for clinical trial in September 2017. We are preparing clinical samples and the initiation of phase I clinical trial. CMAB819 is indicated for the treatment of metastatic non-small cell lung cancer and hepatocellular carcinoma.

CMAB809 (trastuzumab)

CMAB809 (trastuzumab) is our phase I clinical trial biosimilar drug candidate. CMAB809 was approved by the NMPA for clinical trial in April 2017. We completed the preparation of clinical samples and are preparing the initiation of phase I clinical trial. CMAB809 is indicated for the (adjuvant) treatment of HER2 overexpressing breast cancer or metastatic gastric cancer.

CMAB815 (adalimumab)

CMAB815 (adalimumab) is our IND-filing-stage biosimilar drug candidate. It is under evaluation for clinical trial approval by China’s Center for Drug Evaluation, which we expect to receive by December 2019. CMAB815 is indicated for the treatment of rheumatoid arthritis.

CMAB810 (pertuzumab)

CMAB810 (pertuzumab) is our pre-clinical trial biosimilar drug candidate. The related screening processes, the establishment of a cell bank, and a lab-scale process for CMAB810 have been completed. The pilot processes are being developed. CMAB810 is indicated for the treatment of breast cancer.

CMAB813 (palivizumab)

CMAB813 (palivizumab) is our pre-clinical trial biosimilar drug candidate. The related screening processes and the establishment of a cell bank have been completed. The pilot processes are being developed. CMAB813 is indicated for the prevention of severe lower respiratory tract disease caused by RSV in pediatric patients.

CMAB816 (canakinumab)

CMAB816 (canakinumab) is our pre-clinical trial biosimilar drug candidate. The related screening processes and the establishment of a cell bank have been completed. The pilot processes are being developed. CMAB816 is indicated for the treatment of periodic fever syndrome and systemic juvenile idiopathic arthritis.